Consun Pharmaceutical Group (HKG:1681) reported a 16.1% increase in profit attributable to equity shareholders for 2024 to 910.5 million yuan from 784.5 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share were 1.09 yuan, an 11.2% increase from 0.98 yuan the previous year.
Revenue increased by 14.6% to 2.97 billion yuan from 2.59 billion yuan in the prior year.
The board recommended a final dividend of HK$0.30 per share.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。